Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
Our Global Capability Center (GCC) in Bengaluru drives our major software development initiatives. Complementing this, our Bengaluru facility manufactures antibodies for research and diagnostics. Through these integrated technology and biotech operations, we are proud to contribute to India’s growth story in the life sciences sector.
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
Union Health Minister highlights India’s progress in universal health coverage, digital health, AI strategy and global vaccine cooperation during plenary session in Geneva
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The upgraded Rajajipuram centre now features enhanced retina services and advanced OCT technology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
